ClinConnect ClinConnect Logo
Search / Trial NCT06597071

Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely

Launched by NEURALIGHT · Sep 11, 2024

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

As a part of the study, about 40 subjects will undergo a neurological evaluation including motor and cognitive assessments and a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (Tobii, CE-marked class B approved device). Test duration will be approx. 20 minutes. The oculometric evaluation will occur for at least 50% of the cohort 3 times (at baseline, at 6-months and at 12-month follow-up), and all subjects will be recruited over a period of 9 months. All assessments will be performed during a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Men and women, age between 40 and 80 years
  • \<5 years since disease diagnosis
  • Normal or corrected vision
  • MOCA score ≥ 20
  • Ability to follow instructions
  • Willing and able to sign an informed consent form Specific
  • PD cohort: Ages 50-80, Hoehn \& Yahr scale 1-3
  • PSP cohort: diagnosed according to actual diagnostic criteria from Höglinger GU et al, 2017.
  • MSA cohort: diagnosed according to actual diagnostic criteria from Wenning et al, 2022.
  • Exclusion Criteria:
  • -

About Neuralight

Neuralight is a pioneering clinical trial sponsor focused on advancing innovative therapeutic solutions for neurological disorders. With a commitment to enhancing patient outcomes through cutting-edge research and development, Neuralight leverages state-of-the-art technology and a multidisciplinary approach to drive clinical trials that prioritize safety, efficacy, and patient-centric care. The organization collaborates with leading researchers, healthcare professionals, and regulatory bodies to ensure the highest standards of scientific rigor and ethical practices in its clinical investigations. Through its dedication to transforming the landscape of neurology, Neuralight aims to deliver breakthrough treatments that improve the quality of life for individuals affected by complex neurological conditions.

Locations

Sevilla, , Spain

Patients applied

0 patients applied

Trial Officials

Pablo Mir, MD

Principal Investigator

IBIS (Instituto de Biomedicina de Sevilla), Calle Antonio Maura Montaner, Seville, Spain

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported